No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy
In: Haematologica Haematologica, Ferrata Storti Foundation, 2018, 103 (4), pp.e158-e161. ⟨10.3324/haematol.2017.182634⟩ Baliakas, P, Mattsson, M, Hadzidimitriou, A, Minga, E, Agathangelidis, A, Sutton, L, Scarfo, L, Davis, Z, Yan, X, Plevova, K, Sandberg, Y, Vojdeman, F J, Tzenou, T, Chu, C C, Veronese, S, Mansouri, L, Smedby, K E, Giudicelli, V, Nguyen-khac, F, Panagiotidis, P, Juliusson, G, Anagnostopoulos, A, Lefranc, M, Trentin, L, Catherwood, M, Montillo, M, Niemann, C U, Langerak, A W, Pospisilova, S, Stavroyianni, N, Chiorazzi, N, Oscier, D, Jelinek, D F, Shanafelt, T, Darzentas, N, Belessi, C, Davi, F, Ghia, P, Rosenquist, R & Stamatopoulos, K 2018, ' No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy ', Haematologica, vol. 103, no. 4, pp. e158-e161 https://doi.org/10.3324/haematol.2017.182634 Haematologica, 103(4), e158-e161 NARCIS Europe PubMed Central Haematologica, 103(4), E158-E161. Ferrata Storti Foundation; (2018-03-23)
Online
unknown
Zugriff:
The overall survival (OS) of patients with chronic lymphocytic leukemia (CLL) has improved over the last decades mainly due to advances in the understanding of the disease biology and the introduction of novel therapeutic approaches(1). In the present retrospective study we investigated trends in OS in subgroups of cases defined by genetic and immunogenetic features aiming at addressing the question whether advances in chemoimmunotherapy had a uniform impact across all CLL patients. We found that such advances have translated into prolonged OS in all prognostic subgroups examined except those carrying TP53 abnormalities, as expected, but also those assigned to stereotyped subsets #1 and #2, that are generally devoid of such gene aberrations. This latter finding, reported here for the first time, indicates the need for alternative treatment options for these patients.
| Titel: |
No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy
|
|---|---|
| Autor/in / Beteiligte Person: | Tzenou, Tatiana ; Rosenquist, Richard ; Lefranc, Marie-Paule ; Plevová, Karla ; Chu, Charles C. ; Sandberg, Yorick ; Juliusson, Gunnar ; Giudicelli, Véronique ; Trentin, Livio ; Catherwood, Mark ; Davi, Frederic ; Pospíšilová, Šárka ; Yan, Xiao-Jie ; Veronese, Silvio ; Sutton, Lesley-Ann ; Carsten Utoft Niemann ; Darzentas, Nikos ; Stamatopoulos, Kostas ; Anagnostopoulos, Achilles ; Jelinek, Diane F. ; Oscier, David ; Mattsson, Mattias ; Chiorazzi, Nicholas ; Smedby, Karin E. ; Panagiotidis, Panagiotis ; Belessi, Chrysoula ; Nguyen-Khac, Florence ; Montillo, Marco ; Minga, Eva ; Ghia, Paolo ; Langerak, Anton W. ; Scarfò, Lydia ; Agathangelidis, Andreas ; Shanafelt, Tait D. ; Baliakas, Panagiotis ; Stavroyianni, Niki ; Mansouri, Larry ; Hadzidimitriou, Anastasia ; Davis, Zadie ; Fie Juhl Vojdeman ; Uppsala Universitet [Uppsala] ; Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden ; Institute of Applied Biosciences, Centre for Research and Technology-Hellas, Thessaloniki, Greece ; Department of Immunology, Genetics and Pathology [Uppsala, Sueden] (IGP) ; University, Uppsala ; Department of Hematology [Uppsala] ; Università Vita-Salute San Raffaele, Milan, Italy. ; Strategic Research Program in CLL, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy ; Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden ; Università Vita e Salute ; San Raffaele, Milano, Italy ; Strategic Research Program in CLL, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy. ; Department of Haematology, Royal Bournemouth Hospital, Bournemouth, UK. ; The Feinstein Institute for Medical Research ; CEITEC-Central European Institute of Technology, MasarykBrno, Czech Republic. ; Central European Institute of Technology [Brno] (CEITEC MU) ; Brno University of Technology [Brno] (BUT) ; Erasmus University Medical Center [Rotterdam] (Erasmus MC) ; Department of Hematology, Rigshospitalet, Copenhagen, Denmark ; First Department of Propaedeutic Medicine, University of Athens, Athens, Greece ; Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico ; Department of Medicine Solna, Clinical Epidemiology Unit, Karolinska Institutet, and Hematology Center, Karolinska University Hospital, Stockholm, Sweden ; Institut de génétique humaine (IGH) ; Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS) ; Service d'Hématologie clinique [CHU Pitié-Salpêtrière] ; CHU Pitié-Salpêtrière [AP-HP] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU) ; Hematology and Transplantation ; Lund Strategic Research Center for Stem Cell Biology and Cell Therapy ; Lund University and Hospital Department of Hematology, Lund Stem Cell Center, Lund, Sweden ; Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece ; Universita degli Studi di Padova ; Venetian Institute Molecular Medicine (VIMM) ; Department of Hemato-Oncology, Belfast City Hospital, Belfast, UK ; University Hospital Brno ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU) ; Department of Immunology, Mayo Clinic, Rochester, MV, USA ; Mayo Clinic [Rochester] ; Hematology Department, Nikea General Hospital, Piraeus, Greece ; Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden. ; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden ; Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece. ; Institute of Applied Biosciences, Thessaloniki, Greece. ; Department of Immunology ; Baliakas, Panagioti ; Mattsson, Mattia ; Agathangelidis, Andrea ; Scarfo, Lydia ; Plevova, Karla ; Vojdeman, Fie J ; Chu, Charles C ; Smedby, Karin E ; Panagiotidis, Panagioti ; Anagnostopoulos, Achille ; Niemann, Carsten U ; Langerak, Anton W ; Pospisilova, Sarka ; Chiorazzi, Nichola ; Jelinek, Diane F ; Shanafelt, Tait ; Darzentas, Niko ; Immunology |
| Link: | |
| Quelle: | Haematologica Haematologica, Ferrata Storti Foundation, 2018, 103 (4), pp.e158-e161. ⟨10.3324/haematol.2017.182634⟩ Baliakas, P, Mattsson, M, Hadzidimitriou, A, Minga, E, Agathangelidis, A, Sutton, L, Scarfo, L, Davis, Z, Yan, X, Plevova, K, Sandberg, Y, Vojdeman, F J, Tzenou, T, Chu, C C, Veronese, S, Mansouri, L, Smedby, K E, Giudicelli, V, Nguyen-khac, F, Panagiotidis, P, Juliusson, G, Anagnostopoulos, A, Lefranc, M, Trentin, L, Catherwood, M, Montillo, M, Niemann, C U, Langerak, A W, Pospisilova, S, Stavroyianni, N, Chiorazzi, N, Oscier, D, Jelinek, D F, Shanafelt, T, Darzentas, N, Belessi, C, Davi, F, Ghia, P, Rosenquist, R & Stamatopoulos, K 2018, ' No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy ', Haematologica, vol. 103, no. 4, pp. e158-e161 https://doi.org/10.3324/haematol.2017.182634 Haematologica, 103(4), e158-e161 NARCIS Europe PubMed Central Haematologica, 103(4), E158-E161. Ferrata Storti Foundation; (2018-03-23) |
| Veröffentlichung: | HAL CCSD, 2018 |
| Medientyp: | unknown |
| ISSN: | 0390-6078 (print) ; 1592-8721 (print) |
| Schlagwort: |
|
| Sonstiges: |
|